Summary
5.97 -0.42(-6.50%)05/17/2024
Verve Therapeutics Inc (VERV)
Verve Therapeutics Inc (VERV)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -4.06 | 2.50 | -26.74 | -43.89 | -67.11 | -62.06 | 0.00 | -66.76 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 6.15 | |
| Open | 6.46 | |
| High | 6.46 | |
| Low | 6.05 | |
| Volume | 771,914 | |
| Change | -0.26 | |
| Change % | -4.06 | |
| Avg Volume (20 Days) | 854,719 | |
| Volume/Avg Volume (20 Days) Ratio | 0.90 | |
| 52 Week Range | 5.84 - 21.42 | |
| Price vs 52 Week High | -71.29% | |
| Price vs 52 Week Low | 5.31% | |
| Range | -4.80 | |
| Gap Up/Down | -0.27 | |
Fundamentals | ||
| Market Capitalization (Mln) | 470 | |
| EBIDTA | 0 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 66.75 | |
| Book Value | 8.0060 | |
| Earnings Per Share | -7.3070 | |
| EPS Estimate Current Quarter | -0.4800 | |
| EPS Estimate Next Quarter | -0.6100 | |
| EPS Estimate Current Year | -5.5700 | |
| EPS Estimate Next Year | -2.5200 | |
| Diluted EPS (TTM) | -7.3070 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | 0.0000 | |
| Return on asset (TTM) | 0.0000 | |
| Return on equity (TTM) | 0.0000 | |
| Revenue TTM | 0 | |
| Revenue per share TTM | 0.0000 | |
| Quarterly Revenue Growth (YOY) | 0.0000 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 0 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 4.0871 | |
| Revenue Enterprise Value | 0.0000 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 48,171,000 | |
| Shares Float | 26,297,518 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 7.68 | |
| Institutions (%) | 57.66 | |
05/18 11:00 EST - accesswire.com
IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Verve Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / May 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Verve Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / May 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
05/17 12:15 EST - accesswire.com
IMPORTANT SHAREHOLDER INVESTIGATION: The Schall Law Firm Announces it is Investigating Claims Against Verve Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / May 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
IMPORTANT SHAREHOLDER INVESTIGATION: The Schall Law Firm Announces it is Investigating Claims Against Verve Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / May 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
05/17 06:27 EST - investorplace.com
Wall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for May 2024
The ARK Innovation ETF (NYSEARCA: ARKK ) has come under the spotlight recently, and there are three Cathie Wood stocks to buy with strong buy ratings for investors to consider in May this year. One of the key characteristics of the ARK Innovation ETF is its concentrated portfolio, typically holding between 35 to 55 stocks.
Wall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for May 2024
The ARK Innovation ETF (NYSEARCA: ARKK ) has come under the spotlight recently, and there are three Cathie Wood stocks to buy with strong buy ratings for investors to consider in May this year. One of the key characteristics of the ARK Innovation ETF is its concentrated portfolio, typically holding between 35 to 55 stocks.
05/16 11:45 EST - accesswire.com
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Verve Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / May 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Verve Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / May 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
05/15 14:30 EST - accesswire.com
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Verve Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / May 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Verve Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / May 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
05/12 16:00 EST - investorplace.com
3 Underappreciated Stocks That Could 10x in 10 Years
Like achieving a hole-in-one, holding a tenbagger is one of the best results any investor could wish for. A term popularized by legendary investor Peter Lynch, these stocks are innovators with the potential to grow exponentially.
3 Underappreciated Stocks That Could 10x in 10 Years
Like achieving a hole-in-one, holding a tenbagger is one of the best results any investor could wish for. A term popularized by legendary investor Peter Lynch, these stocks are innovators with the potential to grow exponentially.
05/08 09:10 EST - zacks.com
Verve Therapeutics (VERV) Reports Q1 Loss, Tops Revenue Estimates
Verve Therapeutics (VERV) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.68. This compares to loss of $0.84 per share a year ago.
Verve Therapeutics (VERV) Reports Q1 Loss, Tops Revenue Estimates
Verve Therapeutics (VERV) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.68. This compares to loss of $0.84 per share a year ago.
05/03 16:01 EST - globenewswire.com
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that on April 30, 2024, the company granted equity awards to ten new employees, pursuant to the company's 2024 Inducement Stock Incentive Plan, as an inducement material to each new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that on April 30, 2024, the company granted equity awards to ten new employees, pursuant to the company's 2024 Inducement Stock Incentive Plan, as an inducement material to each new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).
04/19 10:30 EST - prnewswire.com
Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Verve Therapeutics, Inc. for potential violations of federal securities laws
NEW YORK , April 19, 2024 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a preeminent national shareholder rights litigation firm, announces that it is investigating claimson behalf of investors of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV) for violations of the securities laws. The focus of the investigation is to whether the Company issued false and/or misleading statements and/or did not disclose information pertinent to investors.
Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Verve Therapeutics, Inc. for potential violations of federal securities laws
NEW YORK , April 19, 2024 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a preeminent national shareholder rights litigation firm, announces that it is investigating claimson behalf of investors of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV) for violations of the securities laws. The focus of the investigation is to whether the Company issued false and/or misleading statements and/or did not disclose information pertinent to investors.
04/19 04:00 EST - accesswire.com
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Verve Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / April 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Verve Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / April 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
04/12 04:30 EST - accesswire.com
IMPORTANT INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Verve Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / April 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
IMPORTANT INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Verve Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / April 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
04/06 09:50 EST - fool.com
After a Serious Setback, Is Verve Therapeutics a Buy?
Verve Therapeutics just had a major mishap in a clinical trial. However, it has a backup plan that's already in action.
After a Serious Setback, Is Verve Therapeutics a Buy?
Verve Therapeutics just had a major mishap in a clinical trial. However, it has a backup plan that's already in action.
04/05 07:00 EST - accesswire.com
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Verve Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / April 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against Verve Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / April 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.